边缘区淋巴瘤中伊布替尼的耐药机制。
Resistance mechanism for ibrutinib in marginal zone lymphoma.
机构信息
Division of Hematology, Department of Medicine, and.
Deparment of Pathology, The Ohio State University, Columbus, OH.
出版信息
Blood Adv. 2019 Feb 26;3(4):500-502. doi: 10.1182/bloodadvances.2018029058.
Abstract
The molecular events leading to primary and acquired resistance to ibrutinib in marginal zone lymphoma have not been studied. We describe the first case of MZL with acquired resistance to ibrutinib in which mutations in both (C481S) and are documented.
摘要
导致边缘区淋巴瘤对伊布替尼产生原发和获得性耐药的分子事件尚未被研究。我们描述了首例对伊布替尼获得性耐药的 MZL 病例，该病例中同时存在 和 （C481S）的突变。
相似文献
1
Resistance mechanism for ibrutinib in marginal zone lymphoma.边缘区淋巴瘤中伊布替尼的耐药机制。
Blood Adv. 2019 Feb 26;3(4):500-502. doi: 10.1182/bloodadvances.2018029058.
2
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.在布鲁顿酪氨酸激酶抑制剂治疗期间病情进展的滤泡性淋巴瘤患者的临床病理特征、预后及突变模式
Br J Haematol. 2018 Sep;182(5):718-723. doi: 10.1111/bjh.14857. Epub 2017 Aug 2.
3
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.华氏巨球蛋白血症中的第一代和第二代布鲁顿酪氨酸激酶抑制剂
Hematol Oncol Clin North Am. 2018 Oct;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. Epub 2018 Jul 19.
4
[Ibrutinib prescription in B-cell lymphoid neoplasms].[伊布替尼在B细胞淋巴瘤中的处方应用]
Bull Cancer. 2016 Feb;103(2):127-37. doi: 10.1016/j.bulcan.2015.12.003. Epub 2016 Jan 25.
5
Ibrutinib for mantle cell lymphoma.伊布替尼治疗套细胞淋巴瘤。
Future Oncol. 2016 Feb;12(4):477-91. doi: 10.2217/fon.15.342. Epub 2016 Jan 13.
6
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.B 细胞淋巴瘤患者来源异种移植模型可用于药物发现，也是个性化治疗的平台。
Clin Cancer Res. 2017 Aug 1;23(15):4212-4223. doi: 10.1158/1078-0432.CCR-16-2703. Epub 2017 Mar 27.
7
Ibrutinib for the treatment of Waldenström macroglobulinemia.伊布替尼用于治疗华氏巨球蛋白血症。
Expert Rev Hematol. 2015 Oct;8(5):569-79. doi: 10.1586/17474086.2015.1061427. Epub 2015 Jul 2.
8
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.了解套细胞淋巴瘤中对BTK和BCL2抑制剂的耐药机制：对临床试验设计的启示
Leuk Lymphoma. 2018 Dec;59(12):2769-2781. doi: 10.1080/10428194.2018.1457148. Epub 2018 Jun 18.
9
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.PROTACs介导布鲁顿酪氨酸激酶突变体的降解用于潜在治疗依鲁替尼耐药的非霍奇金淋巴瘤
Leukemia. 2019 Aug;33(8):2105-2110. doi: 10.1038/s41375-019-0440-x. Epub 2019 Mar 11.
10
Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.解析慢性淋巴细胞白血病中依鲁替尼耐药性
J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14.
引用本文的文献
1
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.布鲁顿酪氨酸激酶抑制剂治疗B细胞恶性肿瘤中国专家共识
Exp Hematol Oncol. 2023 Oct 16;12(1):92. doi: 10.1186/s40164-023-00448-5.
2
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.边缘区淋巴瘤中新代 BTK 抑制剂泽布替尼应答的分子相关性。
Blood Adv. 2023 Jul 25;7(14):3531-3539. doi: 10.1182/bloodadvances.2022009412.
3
Postibrutinib relapse outcomes for patients with marginal zone lymphoma.边缘区淋巴瘤患者接受伊布替尼治疗后的复发结局。
Blood Adv. 2023 Jan 10;7(1):88-91. doi: 10.1182/bloodadvances.2022008634.
4
Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.淋巴瘤的靶向治疗和细胞治疗：逃逸机制与创新策略
Front Oncol. 2022 Sep 12;12:948513. doi: 10.3389/fonc.2022.948513. eCollection 2022.
5
Barriers to achieving a cure in lymphoma.淋巴瘤实现治愈的障碍。
Cancer Drug Resist. 2021 Nov 5;4(4):965-983. doi: 10.20517/cdr.2021.66. eCollection 2021.
6
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.循环肿瘤 DNA 用于综合无创监测伊布替尼联合纳武利尤单抗治疗的淋巴瘤。
Blood Adv. 2021 Nov 23;5(22):4674-4685. doi: 10.1182/bloodadvances.2021004528.
7
Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.对布鲁顿酪氨酸激酶抑制剂的耐药性：其在淋巴恶性肿瘤中成功故事的阿喀琉斯之踵。
Blood. 2021 Sep 30;138(13):1099-1109. doi: 10.1182/blood.2020006783.
8
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.BTK 抑制剂耐药突变源于 NF-κB 而非 B 细胞受体信号通路的 PI3K-RAS-MAPK 途径。
Front Immunol. 2021 Jun 10;12:689472. doi: 10.3389/fimmu.2021.689472. eCollection 2021.
9
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.HCK/BTK 抑制剂 KIN-8194 在 MYD88 驱动的淋巴瘤中具有活性，并克服了突变型 BTKCys481 依鲁替尼耐药性。
Blood. 2021 Nov 18;138(20):1966-1979. doi: 10.1182/blood.2021011405.
10
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.针对 B 细胞恶性肿瘤中的布鲁顿酪氨酸激酶使用非共价抑制剂。
J Hematol Oncol. 2021 Mar 6;14(1):40. doi: 10.1186/s13045-021-01049-7.
本文引用的文献
1
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.在复发/难治性边缘区淋巴瘤中使用依鲁替尼靶向布鲁顿酪氨酸激酶。
Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.
2
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.复发/难治性套细胞淋巴瘤中依鲁替尼治疗的预测因素及结果——一项“真实世界”研究
Hematol Oncol. 2017 Dec;35(4):528-535. doi: 10.1002/hon.2380. Epub 2017 Jan 8.
3
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.循环肿瘤 DNA 揭示淋巴瘤中独特的生物学亚型和基因组进化模式。
Sci Transl Med. 2016 Nov 9;8(364):364ra155. doi: 10.1126/scitranslmed.aai8545.
4
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
5
Postibrutinib outcomes in patients with mantle cell lymphoma.套细胞淋巴瘤患者接受伊布替尼治疗后的结局。
Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13.
6
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.伊布替尼治疗中断的病因及慢性淋巴细胞白血病患者的结局。
JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.
7
Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.美国非霍奇金淋巴瘤亚型分布、地理人口统计学模式和生存情况：1998 年至 2011 年国家癌症数据库的纵向分析。
Am J Hematol. 2015 Sep;90(9):790-5. doi: 10.1002/ajh.24086. Epub 2015 Jul 27.
8
Targeted therapies in CLL: mechanisms of resistance and strategies for management.慢性淋巴细胞白血病的靶向治疗：耐药机制与管理策略
Blood. 2015 Jul 23;126(4):471-7. doi: 10.1182/blood-2015-03-585075. Epub 2015 Jun 11.
9
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.套细胞淋巴瘤患者伊布替尼治疗失败后，不太可能对挽救性化疗有反应，且预后不良。
Ann Oncol. 2015 Jun;26(6):1175-1179. doi: 10.1093/annonc/mdv111. Epub 2015 Feb 23.
10
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.针对PI3K抑制的细胞周期重编程克服了套细胞淋巴瘤纵向功能基因组学揭示的复发特异性C481S BTK突变。
Cancer Discov. 2014 Sep;4(9):1022-35. doi: 10.1158/2159-8290.CD-14-0098. Epub 2014 Jul 31.
Zotero 插件